<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140188</url>
  </required_header>
  <id_info>
    <org_study_id>RISA-19-01</org_study_id>
    <nct_id>NCT04140188</nct_id>
  </id_info>
  <brief_title>SLNB After Nipple Sparing Mastectomy</brief_title>
  <official_title>Sentinel Lymph Node Biopsy After Nipple Sparing Mastectomy: Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acibadem University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acibadem University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sentinel Lymph Node Biopsy (SLNB) after nipple sparing mastectomy (NSM) is controversial.
      This study aims to investigate feasibility of SLNB with radioisotope method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volunteer patients who has underwent to NSM at least more than 6 months prior will be
      included to the study. Radioisotope will be injected via intradermal route to the breast
      underwent to NSM patients and lymphoscintigraphy images will be obtained to detect activity
      in axilla. If hot nodule is detected then it will be concluded that SLNB can be performed
      after NSM.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enhancement in axilla</measure>
    <time_frame>4 hours after injection</time_frame>
    <description>Hot nodules will be showed in axilla after injection of SENTI-SCINT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sentinel Lymph Node Biopsy</condition>
  <condition>Mastectomy, Subcutaneous</condition>
  <arm_group>
    <arm_group_label>Axilla no touch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteer patients who did not underwent to SLNB or axillary lymph node dissection during previous NSM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axilla with previous SLNB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteer patients who has underwent to SLNB but not axillary lymph node dissection during previous NSM</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Senti-Scint (99mTc- pertechnetate combined with human albumin)</intervention_name>
    <description>Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.</description>
    <arm_group_label>Axilla no touch</arm_group_label>
    <arm_group_label>Axilla with previous SLNB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: NSM with/without SLNB at least 6 months prior to this study -

        Exclusion Criteria: previous axillary dissection and active breast cancer

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast cancer is rarely seen in male patients and NSM is not performed thus study group consist of female volunteers.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Halil KARA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Acibadem University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Halil KARA</last_name>
    <phone>+905326073933</phone>
    <email>halil.kara@acibadem.edu.tr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Akif Enes Arikan</last_name>
    <phone>+905308222345</phone>
    <email>enes.arikan@acibadem.com.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Acibadem Maslak Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Sariyer</state>
        <zip>34457</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Halil KARA</last_name>
      <phone>5326073933</phone>
      <email>halil.kara@acibadem.edu.tr</email>
    </contact>
    <contact_backup>
      <last_name>Akif Enes Arikan</last_name>
      <phone>+905308222345</phone>
      <email>enes.arikan@acibadem.com.tr</email>
    </contact_backup>
    <investigator>
      <last_name>Halil KARA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Intra M, Veronesi P, Gentilini OD, Trifir√≤ G, Berrettini A, Cecilio R, Colleoni M, Rietjens M, Luini A, Paganelli G, Veronesi U. Sentinel lymph node biopsy is feasible even after total mastectomy. J Surg Oncol. 2007 Feb 1;95(2):175-9.</citation>
    <PMID>17262724</PMID>
  </reference>
  <reference>
    <citation>Karam A, Stempel M, Cody HS 3rd, Port ER. Reoperative sentinel lymph node biopsy after previous mastectomy. J Am Coll Surg. 2008 Oct;207(4):543-8. doi: 10.1016/j.jamcollsurg.2008.06.139. Epub 2008 Jul 21.</citation>
    <PMID>18926457</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>October 26, 2019</last_update_submitted>
  <last_update_submitted_qc>October 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Acibadem University</investigator_affiliation>
    <investigator_full_name>Halil KARA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Pertechnetate Tc 99m</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

